Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
(NASDAQ:HIND) CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, today announced the interim results from its investigator-initiated Phase 2 PoC study of VT-1953 topical gel in patients with malignant fungating wounds (“MFW”). The interim results were first presented at the recent annual meeting of the American Association for Cancer Research. Vyome Co-founder Dr. Shiladitya Sengupta will host a live video conference on Monday, September 8, to
Related Questions
How will the interim Phase 2 results affect Vyome's upcoming FDA submission timeline and regulatory expectations?
What is the potential market size and revenue upside from the malignant fungating wound (MFW) indication compared to existing treatments?
Are there any safety signals or risk factors in the interim data that could influence investor sentiment and the stock price?